Immunoglobulin (H-Gamma1_L-Kappa)_Scfvkh-G1(H-Ch2-Ch3), Anti-[Homo Sapiens Klk2 (Kallikrein-2, Kallikrein Related Peptidase 2, Kallikrein 2 Prostatic) And Anti-[Homo Sapiens Cd3E (Cd3 Epsilon, Leu-4)], Homo Sapiens And Humanized Monoclonal Antibody, Bispecific, Bivalent
Prostate Neoplasm
Explore 70 assets in Prostate Neoplasm →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Janssen Research & Development, LLC
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07319871CT.gov A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer | — | Recruiting | — | — | — |
NCT07082920CT.gov A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | — | Recruiting | — | — | — |
NCT06095089CT.gov A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04898634CT.gov A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04644770CT.gov A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin (H-Gamma1_L-Kappa)_Scfvkh-G1(H-Ch2-Ch3), Anti-[Homo Sapiens Klk2 (Kallikrein-2, Kallikrein Related Peptidase 2, Kallikrein 2 Prostatic) And Anti-[Homo Sapiens Cd3E (Cd3 Epsilon, Leu-4)], Homo Sapiens And Humanized Monoclonal Antibody, Bispecific, Bivalent (this asset) | Janssen Research & Development, LLC | P1 | C · 39 |
| Docetaxel | Merck Sharp & Dohme LLC | P4 | BBB |
| Prednisone | Merck Sharp & Dohme LLC | P3 | BBB |
| Degarelix | Novartis Pharmaceuticals | P4 | BBB |
| Abiraterone | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Leuporelin | Dana-Farber Cancer Institute | P4 | BB |
| Radium Ra-223 | Bayer | P3 | BB |
| Gozetotide | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Prednisolone | Eli Lilly and Company | P3 | BB |
+42 more in the Prostate Neoplasm cohort
Other indications for Immunoglobulin (H-Gamma1_L-Kappa)_Scfvkh-G1(H-Ch2-Ch3), Anti-[Homo Sapiens Klk2 (Kallikrein-2, Kallikrein Related Peptidase 2, Kallikrein 2 Prostatic) And Anti-[Homo Sapiens Cd3E (Cd3 Epsilon, Leu-4)], Homo Sapiens And Humanized Monoclonal Antibody, Bispecific, Bivalent
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P3 | BB · 66 |
| Adenocarcinoma | — | P1 | CC · 43 |
| Prostate Cancer | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin (H-Gamma1_L-Kappa)_Scfvkh-G1(H-Ch2-Ch3), Anti-[Homo Sapiens Klk2 (Kallikrein-2, Kallikrein Related Peptidase 2, Kallikrein 2 Prostatic) And Anti-[Homo Sapiens Cd3E (Cd3 Epsilon, Leu-4)], Homo Sapiens And Humanized Monoclonal Antibody, Bispecific, Bivalent in Prostate Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-h-gamma1-l-kappa-scfvkh-g1h-ch2-ch3-anti-homo-sapiens-klk2-kallikrein-2-kallikrein-related-peptidase-2-kallikrein-2-prostatic-and-anti-homo-sapiens-cd3e-cd3-epsilon-leu-4-homo-sapiens-and-humanized-monoclonal-antibody-bispecific-bivalent-prostate-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →